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ARTICLE
Fortilin binds IRE1α and prevents ER stress from
signaling apoptotic cell death
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Heather L. Stevenson4,5, Yanjie Chen1, Patuma Sinthujaroen1, Owen M. McDougal3 & Ken Fujise 1,2,5
The endoplasmic reticulum, the cytoplasmic organelle that matures a massive amount of
nascent secretory polypeptides, is particularly sensitive to stress. Endoplasmic reticulum
stress causes unfolded proteins to populate the organelle, eliciting the unfolded protein
response. During the unfolded protein response, GRP78—an endoplasmic reticulum master
stress regulator—detaches from three endoplasmic reticulum stress sensors (IRE1α, PERK,
and ATF6) and allows them to activate the apoptotic signaling pathway. Fortilin,
a pro-survival molecule, is known to inhibit apoptosis by binding and inhibiting p53, but its
role in endoplasmic reticulum stress-induced apoptosis remains unknown. Here, we report
that fortilin directly interacts with the cytoplasmic domain of IRE1α, inhibits both kinase and
endoribonuclease (RNase) activities of the stress sensor, and protects cells against apoptotic
cell death at both cellular and whole animal levels. Our data support a role of fortilin in the
unfolded protein response and its potential participation in human diseases caused by
unfolded protein response.
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Precipitated by nutrient deprivation, hypoxia, and reactiveoxygen species, endoplasmic reticulum (ER) stress causesprotein folding to slow and unfolded proteins to accumu-
late in the organelle, eliciting the unfolded protein response
(UPR). The UPR is a cellular process highly conserved across
species that is designed to restore and enhance the ability of the
ER to fold and process proteins and to avoid the catastrophic
outcome (i.e., death of the organism) of uncontrolled and over-
whelming accumulation of misfolded proteins1. During the UPR,
GRP78 (also known as BiP)—an ER resident master stress reg-
ulator protein—detaches from three key ER transmembrane
stress sensors (IRE1, PERK, and ATF6) to bind and sequester
defective proteins. When freed from the binding and suppression
of GRP78, IRE1, PERK, and ATF6 become activated and initiate
the UPR2.
Mammalian IRE1 has two isoforms—widely expressed IRE1α3
and sparsely expressed IRE1β4. IRE1β is expressed only in the
epithelium of the gastrointestinal tract5 and is absent in the liver
and pancreas5. IRE1β processes 28S ribosomal RNA, but not
X-box-binding protein 1 (XBP1) messenger RNA (mRNA)6, and
participates in mucosal secretion7 and lipid transport in the gut8.
On the other hand, IRE1α is ubiquitously expressed and plays a
major role in how cells and organisms respond to ER stress2.
The cytosolic portion of IRE1α contains the kinase and
endoribonuclease (RNase) domains. After the luminal portion of
IRE1α dissociates from GRP78, IRE1α oligomerizes and
trans-autophosphorylates, leading to activation of its kinase and
RNase domains. When activated, the RNase domain of IRE1α
splices XBP1 mRNA to produce XBP1s, which is an active
transcriptional factor that induces genes related to ER membrane
biogenesis and cell homeostasis9. The kinase domain of activated
IRE1α (P-IRE1α), on the other hand, activates Jun N-terminal
kinase (JNK) by recruiting first the scaffold protein TRAF210 and
then the apoptosis signal-regulating kinase (ASK1)11, which
phosphorylates JNK and activates the JNK pro-apoptotic
pathway12. Activated JNK not only phosphorylates and
inactivates the anti-apoptotic proteins B-cell lymphoma (BCL)-2,
BCL-XL, and myeloid cell leukemia protein 1 (MCL1), but it also
phosphorylates and activates the BH-3-domain-only pro-
apoptotic proteins such as BID and BIM13. The activation of
IRE1α causes the cell to apoptose when pro-apoptotic predis-
position overcomes homeostatic and reparatory propensity
within the cell. However, the mechanism of this dichotomy is
poorly understood14.
Originally cloned in 1989 as a molecule abundantly expressed
in tumor cells15, fortilin is a 172-amino-acid (aa) polypeptide
present in the nucleus, cytosol, and extracellular space16, 17.
Fortilin is also known as translationally controlled tumor protein.
While implicated in diverse cellular functions18, 19, fortilin pos-
sesses potent anti-apoptotic activity16, 20–22. Despite the well-
documented anti-apoptotic activity of fortilin, its precise role in
ER stress-induced apoptotic cell death remains unknown.
Herein we report that fortilin protects cells against ER stress-
induced apoptosis by directly and preferentially binding P-IREα
and preventing it from cleaving XBP1 and activating the JNK
apoptosis pathway. At the whole animal level, fortilin protected
mice against liver failure and death induced by hepatocyte ER
stress. We propose that the fortilin-IRE1α interaction is one of
the important mechanisms by which cells mitigate ER stress-
induced apoptotic cell death.
Results
ER stress translocates fortilin from nucleus to cytosol. To test
whether fortilin changes its intracellular localization upon ER
stress, we stimulated the PC3 human prostate cancer cell line with
either thapsigargin (TG) or the epidermal growth factor (EGF)
fused to the proteolytic A subunit of a bacterial AB5 toxin (SubA)
(EGF-SubA), subjected cells to subcellular fractionation, and
quantified fortilin concentrations in the nuclear, cytosolic, and ER
fractions using immunoblot analysis. TG is a well-characterized
ER stress-inducing agent23 that induces ER stress in the cell
by binding to and inhibiting Ca2+-ATPase, an ER resident
transmembrane protein that maintains Ca2+ homeostasis24.
EGF-SubA is an engineered fusion protein25. When exposed to
EGF-SubA, cells expressing the EGF receptor internalize the
fusion molecule into the cytosol. EGF-SubA is then retrogradely
transported via the Golgi system to the ER lumen26, where it
selectively and rapidly cleaves and destroys GRP7825, 27. Because
GRP78 is the only known substrate of SubA27, EGF-SubA
represents a highly specific inducer of ER stress. At the baseline,
fortilin was present in all three fractions (Fig. 1a, a1, a3, c1, c3, e1,
and e3; Supplementary Fig. 6). Upon ER stress induced by either
TG or EGF-SubA, fortilin concentration decreased in the nuclear
fractions (Fig. 1a, from a1 to a2; from a3 to a4) and increased in
the cytosolic fractions (Fig. 1a, from c1 to c2; from c3 to c4).
Consistently, immunocytochemistry of human osteosarcoma
U2OS cells showed that TG-induced ER stress caused the fortilin
signal in the nucleus to decrease and that in the perinuclear zone
of the cytosol to increase (Supplementary Fig. 1A). Together,
these data suggest that ER stress translocates fortilin from the
nucleus to the ER region of the cytosol.
Fortilin protects cells against ER-stress-induced apoptosis. To
test whether fortilin can protect cells against ER stress-induced
apoptosis, we generated PC3 cells lacking fortilin (PC3sh-Fortilin)
by lentivirally introducing short-hairpin-RNA against fortilin
(sh-Fortilin) into the cell. PC3sh-Fortilin expressed significantly less
fortilin than did the control cells (PCsh-Empty) (Fig. 1b;
Supplementary Fig. 6). Next, we challenged these cells with either
TG (Fig. 1c) or EGF-SubA (Fig. 1d) and quantified the degree of
DNA fragmentation. Both TG and EGF-SubA dose-dependently
induced DNA fragmentation in both PC3sh-Empty and
PC3sh-Fortilin cells (Fig. 1c, d). However, PC3sh-Empty cells exhib-
ited significantly less DNA fragmentation than did PC3sh-Fortilin
cells at all concentrations of TG and EGF-SubA (Fig. 1c, d). These
data indicate that fortilin protected PC3 cells against ER stress-
induced apoptosis. Next, we generated U2OS cells overexpressing
fortilin (U2OSFortilin-HA) and control cells (U2OSEmpty-HA) (Sup-
plementary Figs. 1B and 9), challenged the cells with TG, and
assessed the survival (Supplementary Fig. 1C) and degree of DNA
fragmentation (Supplementary Fig. 1D) of these cells. Fortilin
protected the U2OS cells against TG-induced cell death and DNA
fragmentation (Supplementary Fig. 1C, D).
To evaluate how fortilin modulates ER stress-induced apop-
tosis and necrosis, we challenged PC3sh-Fortilin and PC3sh-Empty
cells with either TG or EGF-SubA, stained them with fluorescein
isothiocyanate (FITC)-conjugated Annexin V and propidium
iodide (PI), and analyzed them using flow cytometry. Upon TG
and EGF-SubA challenge, PC3sh-Fortilin cells bound more Annexin
V than did PC3sh-Empty cells (Fig. 1e, Apoptosis; *P< 0.05 by two-
tailed unpaired t-test), although there was no difference in PI
levels between the two groups of cells (Fig. 1e, Necrosis; NS= not
statistically significant). These data suggest that fortilin protected
PC3 cells against ER stress-induced apoptosis but not against
necrosis (Fig. 1e).
To assess the role of fortilin in the ER stress-induced activation
of caspases, we challenged PC3sh-Fortilin and PC3sh-Empty cells with
either TG or EGF-SubA, and subjected the cell lysates to
immunoblot analysis (Fig. 1f, g; Supplementary Fig. 6). Both
TG and EGF-SubA induced more cleavage of caspases-9 and -3
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and PARP in PC3sh-Fortilin than in PC3sh-Empty cells (Fig. 1f for
TG: caspase-9, c2 and c3 vs. c5 and c6; caspase-3, e2 and e3 vs. e5
and e6; PARP, g2 and g3 vs. g5 and g6, respectively) (Fig. 1g for
EGF-SubA: caspase-9, c2 and c3 vs. c5 and c6; caspase-3, e2 and
e3 vs. e5 and e6; PARP, g2 and g3 vs. g5 and g6, respectively).
Next, we challenged U2OSEmpty-HA and U2OSFortilin-HA cells with
TG and quantified the activities of caspase-3, -8, and -9. TG dose-
dependently activated caspase-9 and -3 but not -8, as previously
reported28 (Supplementary Fig. 1E). In this system, fortilin
protected TG-challenged U2OS cells against the activation of
caspases-9 and -3 (Supplementary Fig. 1E, ***P< 0.005;
*P< 0.05, both by two-tailed unpaired t-test).
Next, we challenged PC3sh-Fortilin and PC3sh-Empty cells with
either TG or EGF-SubA, fractionated the lysates into cytosolic
and mitochondrial fractions, and subjected them to immunoblot
analysis using anti-cytochrome c antibody. The cytosolic fraction
of PC3sh-Fortilin cells contained a greater amount of cytochrome c
upon TG/EGF-SubA simulation than the control (Fig. 1h; c3 vs.
c4 for TG; f3 vs. f4 for EGF-SubA; Supplementary Fig. 7). The
mitochondrial fraction of PC3sh-Fortilin cells contained a lesser
amount of cytochrome c upon TG/EGF-SubA simulation than
the baseline (Fig. 1h; c7 vs. c8 for TG; f7 vs. f8 for EGF-SubA).
TG/EGF-SubA stimulation did not change the amount of
cytochrome c in the cytosol or mitochondria in PC3sh-Empty cells
(Fig. 1h; c1 vs. c2, c5 vs. c6 for TG; f1 vs. f2, f5 vs. f6 for
EGF-SubA).These data indicate that fortilin prevents cytochrome
c release from mitochondria to the cytosol in TG/EGF-SubA-
stimulated PC3 cells.
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Fig. 1 Fortilin protects cells against apoptosis under ER stress. a ER stress induced by thapsigargin (TG) and the epidermal growth factor (EGF) fused to the
proteolytic A subunit of the bacterial AB5 toxin (SubA) (EGF-SubA) translocates fortilin from the nucleus to the cytosol. PC3 cells were challenged by
either TG or EGF-SubA and their lysates were subjected to subcellular fractionation and immuno-blot analyses (IB). HDAC2 histone deacetylase 2, HSP90
heat shock protein 90. b Generation and characterization of fortilin-deficient PC3 cells. PC3 cells with decreased fortilin expression were generated by
lentivirally introducing shRNA-fortilin into the cells and characterized by IB. c, d Fortilin protects cells against ER stress-induced apoptosis. PC3sh-Fortilin and
PC3sh-Empty cells were challenged by either TG or EGF-SubA and subjected to the DNA fragmentation assay to evaluate the degree of apoptosis. A.U.
arbitrary unit. Data were expressed as means± s.d. (biological replicates [n]= 3) and analyzed by two-tailed unpaired t-test. NS not statistically significant;
*P< 0.05; ***P< 0.005. e Fortilin protects cells against apoptosis, but not necrosis, under TG- and EGF-SubA-induced ER stress. PC3sh-Fortilin and PC3sh-
Empty cells were challenged by either TG or EGF-SubA, stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI), and
analyzed by flow cytometry to evaluate the role of fortilin in the prevention of apoptosis and necrosis. Data were expressed as means± s.d. (n= 3) and
analyzed by two-tailed unpaired t-test. NS not statistically significant; *P< 0.05. f, g Fortilin protects cells against ER stress-induced cleavage of caspase-3,
caspase-9, and PARP. PC3sh-Fortilin and PC3sh-Empty cells were challenged by either TG f or EGF-SubA g and subjected to IB to evaluate the status of the
cleavage and activation of the caspases. The lack of fortilin predisposed PC3 cells to the cleavage of caspase-9, caspase-3, and poly ADP ribose polymerase
(PARP) when challenged by TG- and EGF-SubA. GAPDH glyceraldehyde 3-phosphate dehydrogenase. h Fortilin protects cells against ER stress-induced
release of cytochrome c from the mitochondria into the cytosol. PC3sh-Fortilin and PC3sh-Empty cells were challenged by either TG (the top panel) or
EGF-SubA (the bottom panel). Cell lysates were fractionated into cytosolic and mitochondrial fractions. The levels of cytochrome c in the individual
fractions were evaluated by IB. Tx treatment, HSP60 heat shock protein 60
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Fortilin prevents ER stress from activating IRE1α. EGF-SubA
targets a single protein, namely GRP78, in mammalian cells27.
Cells expressing a SubA-resistant mutant GRP78 (GRP78L416D)
are immune to EGF-SubA27, suggesting that EGF-SubA is a
selective ER stress-inducing agent with minimum off-target
effects. To further study the role of fortilin in ER stress signal-
ing in a system free of potential downstream effects of
TG-induced perturbances in Ca2+24, we performed all remaining
experiments using EGF-SubA. To confirm that EGF-SubA cleaves
GRP78 in PC3 cells, we incubated PC3 cells with 0–20 nM
of EGF-SubA and subjected the lysates to immunoblot analysis
using anti-GRP78 antibody. EGF-SubA dose-dependently
cleaved GRP78 in PC3 cells (Fig. 2a; Supplementary Fig. 7), but
treatment with EGF-SubA did not affect the expression levels of
fortilin in either PC3sh-Fortilin or PC3sh-Empty cells at 24 h (Fig. 2b,
Fortilin in lanes 1–4 and lanes 5–8, respectively; Supplementary
Fig. 7).
During the UPR, GRP78 detaches from the ER transmembrane
stress sensors IRE1α, PERK, and ATF6 to bind and sequester
defective proteins in the ER lumen. When IRE1α, PERK, and
ATF6 are freed from the binding and suppression of GRP78, they
activate various ER stress pathways2. It has been shown that
IRE1α12 and PERK29, but not ATF630, signal ER stress-induced
apoptosis (Fig. 2c). Because fortilin protects cells against ER
stress-induced apoptosis (Fig. 1c–h, Supplementary Fig. 1D, E),
we first assessed whether fortilin blocks either the PERK or IRE1α
pathway by treating PC3sh-Fortilin and PC3sh-Empty cells with EGF-
SubA and subjecting them to immunoblot analysis (Fig. 2d, e;
Supplementary Fig. 7). Both PC3sh-Fortilin and PC3sh-Empty cells
expressed similar amounts of PERK and eukaryotic translation
initiation factor alpha (eIF2α), regardless of the concentrations of
EGF-SubA (Fig. 2d, rows b and d, and the bottom graph). The
cellular levels of phosphorylated eIF2α (P-eIF2α), the active form
of eIF2α, dose-dependently increased in response to EGF-SubA,
and there was no detectable difference in P-eIF2α levels between
PC3sh-Fortilin and PC3sh-Empty cells (Fig. 2d, row c of lanes 1–4 vs.
lanes 5–8, and the bottom graph). Both PC3sh-Fortilin and PC3sh-
Empty cells expressed similar amounts of IRE1α and JNK (both
p54 and p46), regardless of the concentrations of EGF-SubA
(Fig. 2e, rows c and e of lanes 1–4 vs. lanes 5–8, and the bottom
graph). Strikingly, however, PC3sh-Fortilin cells expressed greater
amounts of phosphorylated and activated forms of IRE1α
(P-IRE1α) and JNK (P-JNK) than did PC3sh-Empty cells (Fig. 2e,
rows b and d of lanes 2–4 vs. lanes 6–8). Enzyme-linked
immunosorbent assay (ELISA) analysis of the cell lysates from
PC3sh-Fortilin and PC3sh-Empty cells treated with various
AT
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Fig. 2 Fortilin selectively inhibits IRE1α signaling to protect against ER stress-induced apoptosis. a EGF-SubA dose-dependently cleaves GRP78 in PC3 cells.
Wild-type PC3 cells were treated with the indicated concentrations of EGF-SubA, and their lysates were subjected to IB. b EGF-SubA treatment does not
change the expression levels of fortilin in PC3 cells. PC3sh-Empty and PC3sh-Fortilin cells were treated with the indicated concentrations of EGF-SubA for 24 h
and subjected to IB. c Three branches of ER stress signaling pathways. IRE1α, PERK, and ATF6 are the ER resident transmembrane proteins that signal ER
stress when activated. IRE1α and PERK, but not ATF6, are known to induce apoptosis. d Fortilin does not regulate the PERK and ATF6 signaling pathways.
PC3sh-Empty and PC3sh-Fortilin cells were treated with the indicated concentrations of EGF-SubA, and their lysates were subjected to quantitative IB for PERK,
its downstream molecule eIF2α, and fragmented and activated ATF6 (ATF6f). Data were expressed as means± s.d. (n= 3) and analyzed by two-tailed
unpaired t-test. *P< 0.05; **P< 0.01; ***P< 0.005. e Fortilin inhibits the IRE1α ER stress signaling pathway. PC3sh-Empty and PC3sh-Fortilin cells were treated
with the indicated concentrations of EGF-SubA and subjected to IB for IRE1α and its downstream molecules JNK and spliced XBP1 (XBP1s). P-IRE1α is the
activated form of IRE1α, and P-JNK is the activated form of JNK. Data were expressed as means± s.d. (n= 3, except for P-IRE1α and XBP1s where n= 2)
and analyzed by two-tailed unpaired t-test. *P< 0.05; **P< 0.01; ***P< 0.005. f Fortilin inhibits the processing by IRE1α of XBP1 mRNA. PC3sh-Empty and
PC3sh-Fortilin cells were treated with the indicated concentrations of EGF-SubA. The cDNA from total RNA from these cells was subjected to PCR and Pst1
restriction digestion (CTGCA|G) to semi-quantitatively evaluate the levels of XBP1s. Data were expressed as means± s.d. (n= 2) and analyzed by
two-tailed unpaired t-test. *P< 0.05. XBP1u unspliced XBP1
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concentrations of EGF-SubA also showed that fortilin protected
PC3 cells against the phosphorylation of JNK (Supplementary
Fig. 2). Furthermore, the protein expression and mRNA levels of
XBP1s—the active form of XBP1 generated by P-IRE1α—were
greater in PC3sh-Fortilin than in PC3sh-Empty cells (Fig. 2e, row f of
lanes 2–4 vs. lanes 6–8 and Fig. 2f, lanes 2–4 vs. lanes 6–8,
respectively, and the bottom graphs). Consistent with previous
reports that ATF6 does not participate in ER stress-induced
apoptosis30, we found that fortilin did not affect the cellular levels
of active and fragmented ATF6 (ATF6f) (Fig. 2d, row e of lanes
1–4 and lanes 5–8). These data suggest that fortilin inhibits the
IRE1α branch, but not the PERK or ATF6 branch, of the ER
stress signaling pathway and that the anti-apoptotic activities
(Fig. 1c–h, Supplementary Fig. 1D, E) of fortilin in the setting of
ER stress are mediated through its inhibition of the IRE1α
signaling pathway.
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Fig. 3 Fortilin interacts with the cytosolic domain of IRE1α and inhibits its protein kinase and RNase activities. a Proximity ligation assay (PLA) shows a
specific interaction between fortilin and P-IRE1α in EGF-SubA-treated PC3 cells. The cells were treated with 2 nM EGF-SubA for 24 h and subjected to PLA,
using anti-IREα and anti-P-IRE1α antibodies to evaluate fortilin-IRE1α and fortilin-P-IRE1α interaction, respectively. PLA interaction indices were calculated
by dividing the number of red dots by the number of nuclei, expressed as means± s.d. (n= 3), and analyzed by two-tailed unpaired t-test. NS not
statistically significant; ***P< 0.005. Scale bar= 10 µm. b Fortilin co-immunoprecipitates P-IRE1α. PC3 cells were treated with 2 nM EGF-SubA for 24 h,
lysed and subjected to immunoprecipitation (IP). c Domain structure of human IRE1α. Human IRE1α consists of the ER luminal domain (aa 1–443),
transmembrane domain (aa 444–464), linker region (aa 465–567), kinase domain (aa 568–833), and endoribonuclease (RNase) domain (aa 836–997).
The following recombinant proteins were used for biolayer interferometry: full-length IRE1α (aa 1-977), IRE1α-Myc-DDK (aa 1–977); IRE1α-L, GST-IRE1α (aa
1–70); IRE1α-TM, GST-IRE1α (aa 401–500); and IRE1α-C, GST-IRE1α (aa 468–977). d–h Fortilin binds to P-IRE1α through its cytosolic domain. Biotinylated
fortilin was immobilized to the streptavidin biosensor. Recombinant IRE1α, either full-length or fragment, was applied to the biosensor at various
concentrations, and dissociation constants (Kds, expressed as mean± s.d., n= 3) were derived. i Lowest energy binding pose of fortilin (blue) with
cytosolic domain of IRE1α (green) (the right panel) presented with that of a fortilin-fortilin dimer (the left panel). j Intermolecular interactions between
phosphorylated serine724 (pS724) and serine726 (pS726) of the cytosolic domain of IRE1α with lysine residues (K19 and K34) of fortilin. k Fortilin inhibits
the RNase activity of IRE1α. An in vitro IRE1α RNase activity assay was performed by incubating IRE1α with human recombinant fortilin and the substrate
fluorescently tagged XBP1 RNA stem loop, the cleavage of which would allow the fluorescein amidite (FAM) to fluoresce. Data were expressed as
means± s.d. (n= 4) and analyzed by two-tailed unpaired t-test. ***P< 0.005. l Fortilin inhibits the kinase activity of IRE1α. An in vitro IRE1α kinase activity
assay was performed by incubating IRE1α with [γ-33P]ATP, recombinant fortilin, and myelin basic protein (MBP) as a substrate of the kinase in the kinase
reaction buffer. The phosphorylation index was calculated by dividing the radioactivity of MBP for a given fortilin concentration by that of the vehicle
control and expressed as means± s.d. (n= 2) from which half maximal inhibitory concentration (IC50) was calculated
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Fortilin binds the cytosolic domain of IRE1α. To investigate
how fortilin selectively and negatively regulates IRE1α and its
signaling pathway, we tested whether fortilin binds IRE1α using
the in situ proximity ligation assay (PLA)31. We seeded wild-type
PC3 cells onto glass slides and treated them with either phosphate
buffered saline (PBS) or EGF-SubA before subjecting them to the
PLA using (a) mouse anti-fortilin and (b) rabbit anti-IRE1α or
anti-P-IRE1α antibodies (where anti-IRE1α detects total IRE1α—
both phosphorylated and unphosphorylated—and anti-P-IRE1α
detects only P-IRE1α). Each red dot in Fig. 3a indicates that a
fortilin molecule was within about 30 nm of an IRE1α molecule.
We counted the number of red dots and divided it by the number
of nuclei to calculate the PLA interaction index. EGF-SubA-
induced ER stress drastically increased the number of interactions
between fortilin and P-IRE1α (Fig. 3a, right panel, bars 3 vs. 4)
but not the number of interactions between fortilin and IRE1α
(Fig. 3a, right panel, bars 1 vs. 2).
To further evaluate the interaction between fortilin and
P-IRE1α in vivo, we challenged PC3 cells with 2 nM EGF-SubA
for 24 h and incubated the cleared total cell lysates with either
rabbit anti-fortilin monoclonal antibody (Clone EPR5540) or
rabbit IgG. We precipitated the formed protein–antibody
complexes with Dynabeads™ Protein G (Dynal-ThermoFisher
Scientific, Waltham, MA, USA), washed them extensively, eluted
them into the sodium dodecyl sulfate (SDS) loading buffer, and
subjected them to SDS-polyacrylamide gel electrophoresis
(PAGE) and immunoblotting. The rabbit anti-fortilin antibody,
but not rabbit IgG, successfully immunoprecipitated fortilin
(Fig. 3b, band a2; Supplementary Fig. 7). Both β-actin and
α-tubulin—known fortilin binding proteins32, 33—were co-
immunoprecipitated with fortilin (Fig. 3b, band e2 and f2).
NQO2—a protein known not to interact with fortilin34—was not
co-immunoprecipitated, suggesting that the wash condition was
sufficiently stringent (Fig. 3b, no band in d2). In this system, both
anti-P-IRE1α and anti-IRE1α antibodies detected discrete bands
at the expected molecular weights (Fig. 3b, bands b2 and c2,
respectively). The immunoblot signals of fortilin, P-IRE1α,
IRE1α, β-actin, and α-tubulin (Fig. 3b, bands a2, b2, c2, e2, and
f2, respectively) were from specific protein–protein interactions
and did not represent non-specific interaction between the
proteins and the beads because there were no immuneblot signals
in the sample incubated with the same beads and IgG (Fig. 3b, a3,
b3, c3, d3, e3, and f3). Because anti-IRE1α antibody is known to
detect both non-phosphorylated and phosphorylated IRE1α,
band c2 (Fig. 3b) could be either non-phosphorylated or
phosphorylated IRE1α. Importantly, however, the presence of a
band in the membrane probed by anti-P-IRE1α (Fig. 3b, band b2)
shows the presence of a specific interaction between fortilin and
P-IRE1α. We found the same in PC3 cells treated by TG
(Supplementary Figs. 3A and 9). These data, when taken together,
suggest that fortilin specifically interacts with P-IRE1α.
IRE1α is a transmembrane protein consisting of five distinct
domains—luminal, transmembrane, linker, kinase, and RNase
domains35 (Fig. 3c). To further characterize the direct physical
interaction between fortilin and P-IRE1α, we tested if biolayer
interferometry (BLItz, ForteBio, Menlo Park, CA, USA)36 could
be used to detect the interaction between fortilin and its binding
partners. We first biotinylated and immobilized recombinant
human fortilin (Supplementary Fig. 3B, lane 9) to the
streptavidin-coated biosensor. BLItz appropriately detected the
interaction between fortilin on the biosensor and anti-fortilin
monoclonal antibody in the aqueous phase at the dissociation
constant (Kd) of 71.46± 0.04 nM (mean values± s.d., n= 3,
Supplementary Fig. 3C), whereas no meaningful interaction
between fortilin and albumin was detected (Kd= 1.05± 0.11 mM,
mean values± s.d. n= 3, Supplementary Fig. 3D). Next, we
subjected human recombinant fortilin and IRE1α and its deletion
mutants to the same biolayer interferometry (BLItz)36. Five
different recombinant preparations of IRE1α were tested: IRE1α
(dephosphorylated IRE1α, 1–977 aa, see Supplementary Figs. 3E
and 9), P-IRE1α (phosphorylated IRE1α, 1–977 aa), IRE1α-L (the
N-terminal, luminal portion of IRE1α, 1–70 aa), IRE1α-TM (the
transmembrane portion of IRE1α, 401–500 aa), and
IRE1α-C (the cytosolic portion of IRE1α, 468–977 aa)(Fig. 3c
and Supplementary Fig. 3B, lanes 2, 5, 6, and 7). Fortilin bound
only weakly to IRE1α (Fig. 3d) but tightly to P-IRE1α (Fig. 3e).
Further, fortilin did not bind the luminal or transmembrane
portions of IRE1α (Fig. 3f, g) but bound the cytosolic portion of
IRE1α (Fig. 3h). These data suggest that fortilin specifically and
directly binds to the activated and phosphorylated form of IRE1α
(P-IRE1α) through its cytosolic domain (Fig. 3c–h and Supple-
mentary Fig. 3G).
To further verify the binding of fortilin to IRE1α, we
performed molecular docking and molecular dynamics (MD)
experiments using the methods described in detail in the Methods
section. Because fortilin has been shown to dimerize37, we
performed a molecular docking study for both dimerized fortilins
(fortilin:fortilin) and the fortilin–IRE1α-C complex (fortilin:
IRE1α-C). The binding surface of fortilin that is used to interact
with another fortilin for dimerization (Fig. 3i, the left panel) was
nearly identical to that used to interact with IRE1α-C (Fig. 3i, the
right panel). The relative binding favorability scores for the
fortilin:fortilin and fortilin:IRE1α-C complexes were calculated to
be −879.1 and −945.3 kcal mol−1, respectively, suggesting that the
fortilin:IRE1α-C complex was more thermodynamically stable
than the fortilin:fortilin complex. We then inspected the docking
pose of the fortilin:IRE1α-C complex and found that the main
phosphorylation sites (S724 and S726) of IRE1α38 were positioned
in close proximity to the binding surface of fortilin (especially K19
and K34) regardless of their phosphorylation status, suggesting
that the binding of fortilin to IRE1α blocks the access of anther
IRE1α to the phosphorylation sites (S724 and S726) of the
molecule for trans-autophophorylation. The adenosine dipho-
sphate (ADP) binding region of the kinase domain (R600, E612,
D688, N693, and D711)38 and the RNA processing region of the
RNase domain (Y892, R904, N905, and H909)38 were not positioned
near the binding surface of fortilin, although it is likely that
binding of fortilin to the key phosphorylation sites of IRE1α
induces conformational changes to disrupt the functionality of
these regions38.
Next, we compared the thermodynamic stability of the fortilin–
P-IRE1α complex with that of the fortilin–IRE1α complex using
MD forward and reverse binding free energy simulations. We
found that the fortilin-P–IRE1α complex was substantially more
thermodynamically stable than the fortilin–IRE1α complex by a
ΔGbind value of −15.48 kcal mol−1 (Supplementary Table 1). The
free energy change (ΔG2) due to phosphorylation of IRE1α in the
bound state with fortilin was −602.61± 1.02 kcal mol−1 (mean
values± s.e.), whereas the free energy change (ΔG1) due to
phosphorylation of unbound IRE1α was −587.13± 1.01 kcal mol−1
(mean values± s.e.). Both the forward and reverse simulations,
which correspond to phosphorylation and dephosphorylation of
S724 and S726 of IRE1α, resulted in comparable values, thus
supporting the validity of the calculations. The higher thermo-
dynamic stability of the fortilin–P-IRE1α complex compared to
that of fortilin–IRE1α may be due to the strong electrostatic
forces between the positively charged lysine residues (K19 and
K34) of fortilin and the negative charges of the phosphoserine
residues (S724 and S726) (Fig. 3j). These MD data suggest that
fortilin binds IRE1α in a thermodynamically stable fashion, that
fortilin binds preferentially to P-IRE1α over IRE1α, and that
fortilin binding to P-IRE1α occludes the key phosphorylation
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00029-1
6 NATURE COMMUNICATIONS |8:  18 |DOI: 10.1038/s41467-017-00029-1 |www.nature.com/naturecommunications
sites (S724 and S726) of the molecule and thus can prevent IRE1α
dimerization and subsequent trans-autophosphorylation.
Fortilin inhibits both kinase and RNase activities of IRE1α.
The cytosolic domain of IRE1α contains the kinase and RNase
domains (Fig. 3c). Because fortilin prevented EGF-SubA from
phosphorylating IRE1α (row b of Fig. 2e and Supplementary
Fig. 2) and splicing XBP1 to form XBP1s (Fig. 2f and row f of
Fig. 2e), we tested whether fortilin inhibits the kinase and RNase
activities of IRE1α through its direct interaction with the ER
stress sensor molecule. We first assessed the RNase activity of
IRE1α in the presence of fortilin in vitro using a synthetic mRNA
stem loop corresponding to the XBP1 substrate sequence39. The
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Fig. 4 Fortilin protects the whole animal against ER stress-induced liver failure and death by negatively regulating the IRE1α stress sensor pathway.
a Liver-specific absence of fortilin in fortilinKO-liver mice. *, non-specific bands. b Experimental protocol. i.p. intraperitoneally, MOA mechanism of action,
CMP complete metabolic panel, CBC complete blood count, IHC immunohistochemistry. c Higher survival rates of fortilinWT-liver than fortilinKO-liver mice
after EGF-SubA challenge. A Kaplan–Meier survival curve and log-rank test showed the significantly better survival of fortilinWT-liver mice than that of
fortilinKO-liver mice (n= 10, P< 0.001). d Massive liver damage of EGF-SubA-treated fortilinKO-liver mice. The sera from fortilinWT-liver and fortilinKO-liver
mice, treated with either PBS or EGF-SubA, were assayed for alanine aminotransferase (ALT; n= 5 and 10, for PBS and EGF-SubA, respectively), total
bilirubin (TBIL; n= 3 and 6), and alkaline phosphatase (ALP; n= 3 and 6). Data were expressed as mean and analyzed by two-tailed unpaired t-test.
NS not statistically significant; *P< 0.05; ***P< 0.005. e Drastic gross pathological change in the liver of EGF-SubA-treated fortilinKO-liver mice. Scale bar
= 10 mm. f Fortilin fails to negatively regulate the PERK and ATF6 signaling pathways in the EGF-SubA-challenged liver. The total lysates from the livers of
fortilinWT-liver and fortilinKO-liver mice, after the indicated treatments, were subjected to IB. Data were expressed as means± s.d. (n= 3) and analyzed by
two-tailed unpaired t-test. NS not statistically significant. g Fortilin inhibits the IRE1α signaling pathway in the EGF-SubA-challenged liver. Data were
expressed as means± s.d. (n= 3) and analyzed by two-tailed unpaired t-test. NS not statistically significant; **P< 0.01. h Fortilin blocks IRE1α-mediated
splicing of XBP1 mRNA in the liver of mice under ER stress. The amounts of XBP1s and XBP1u were quantified by quantitative densitometry. Data were
expressed as means± s.d. (n= 5) and analyzed by two-tailed unpaired t-test. ***P< 0.005. i Fortilin inhibits the expression of XBP1s-inducible genes in the
liver of mice under ER stress. Expression levels of ER-associated degradation (ERAD) genes—Edem1 and Herp1—in the liver of EGF-SubA-challenged
fortilinWT-liver and fortilinKO-liver mice were quantified by RT-qPCR with normalization against 18S rRNA. Data were expressed as means± s.d. (n= 4) and
analyzed by two-tailed unpaired t-test. *P< 0.05, **P< 0.01. j Fortilin blocks apoptosis and IRE1α pathway activation in EGF-SubA-challenged liver.
Paraffin sections from the livers of EGF-SubA-treated fortilinWT-liver and fortilinKO-liver mice were subjected to TUNEL, P-IRE1α, and P-JNK staining using
3,3’-diaminobenzidine (DAB) as a chromogen. Data were expressed as means± s.d. (n= 6) and analyzed by two-tailed unpaired t-test. ***P< 0.005. Scale
bar= 50 µm
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stem loop incorporates a fluorescein amidite fluorophore (FAM)
on its 5′ end and the Iowa Black FQ (IBFQ) quencher on its 3′
end, resulting in green fluorescence upon site-specific cleavage by
IRE1α (Fig. 3k, left panel). In this system, fortilin significantly
inhibited the RNase activity of IRE1α (Fig. 3k, right panel, no
fortilin vs. 4 µM of fortilin; ***P< 0.005 by two-tailed unpaired t-
test). Next, we evaluated the effect of recombinant fortilin on the
ability of IRE1α to phosphorylate myelin basic protein (MBP)
in vitro. MBP was used as a generic substrate of serine/threonine
kinases such as IRE1α40, 41 because there is no specific substrate
identified for IRE1α, other than IRE1α itself42. We performed a
standard kinase assay using [γ-33P]ATP as previously described41
and found that fortilin dose-dependently prevented IRE1α from
incorporating γ-33P into MBP, with the half maximal inhibitory
concentration (IC50) being 0.77 µM (Fig. 3l). We also assessed the
phosphorylation of MBP by IRE1α by immunoblot analysis using
anti-phosphoserine antibody (Supplementary Figs. 3F and 9). At
baseline, mild phosphorylation was noted in MBP (Supplemen-
tary Fig. 3F, P-MBP, lane 2). P-IRE1α increased the phosphor-
ylation of MBP (Supplementary Fig. 3F, P-MBP, lane 4 vs. lane 2).
In this system, fortilin decreased the phosphorylation of MBP
(Supplementary Fig. 3F, P-MBP, lanes 4–8). These data suggest
that fortilin binds and inhibits both the kinase and RNase
activities of IRE1α.
Fortilin saves mice from ER stress-induced liver failure. To
study how protection by fortilin against the activation of the
IRE1α pathway manifests itself in the whole animal under ER
stress, we generated a mouse strain that lacks fortilin specifically
in the liver—alb-Cre+/−fortilinflox/flox(fortilinKO-liver)—by cross-
ing transgenic mice overexpressing the albumin-promoter-driven
Cre recombinase (alb-Cre+/−) with fortilinflox/flox mice
(Supplementary Fig. 4A, B, C). These mice appeared normal and
were fertile. The liver of the fortilinKO-liver mice expressed very
little fortilin (Fig. 4a, top panel; Supplementary Fig. 8), whereas
fortilin expression was similar in other organs between
fortilinKO-liver and fortilinWT-liver mice (Fig. 4a, bottom panel).
We then intraperitoneally administered a one-time dose of
EGF-SubA (250 µg kg−1 body weight) to fortilinKO-liver and
fortilinWT-liver mice. The liver expresses the EGF receptor and
thus responds to EGF-SubA43.
The first group of animals (n= 10 per group) were observed for
48 days to assess survival (Fig. 4b, the left arm, “Survival”),
whereas the animals in the second group were sacrificed on day 7,
and the blood and organs were harvested for further analyses
(Fig. 4b, the right arm, the mechanism of action or “MOA”). In
the survival experiment, 80% of fortilinWT-liver mice were still
alive on day 48, whereas none of the fortilinKO-liver mice survived
(all died between days 9 and 12) (P< 0.001 by the Kaplan–Meier
survival curve and log-rank test, Fig. 4c). In the MOA group
(n= 10 each), the complete metabolic panel (CMP) showed a
drastic elevation of liver enzymes—both alanine aminotransferase
(ALT) and alkaline phosphatase (ALP)—in fortilinKO-liver
mice compared with fortilinWT-liver mice, suggesting that
fortilinKO-liver mice sustained far worse liver injury than did
fortilinWT-liver mice (Fig. 4d, ALT and ALP). Consistently, the
liver function of fortilinKO-liver mice was more seriously
compromised than that of fortilinWT-liver mice upon EGF-SubA
challenge, as evidenced by higher total bilirubin levels (Fig. 4d,
TBIL). There was no significant difference between EGF-SubA-
challenged fortilinWT-liver and fortilinKO-liver mice in hemoglo-
bin/hematocrit (H/H) or white blood cell (WBC) counts
(Supplementary Table 2). Upon gross inspection, the livers of
fortilinKO-liver mice were uniformly pale, indicating severe
functional impairment of the organ (Fig. 4e, EGF-SubA of
fortilinKO-liver). The kidney and pancreas were not affected by
EGF-SubA challenge (Supplementary Fig. 4D, blood urea
nitrogen [BUN] and creatinine [CRE] for renal function
and amylase [AMY] for pancreas). These data suggest that
fortilinKO-liver mice died of acute liver failure in response to
EGF-SubA challenge.
Fortilin blocks IRE1α from signaling apoptosis in the liver. We
then tested whether fortilin negatively regulated IRE1α in vivo, as
we saw in the cellular and in vitro systems described above
(Figs. 1, 2, and 3). Immunoblot analyses showed that fortilin
expression was severely decreased in the livers of fortilinKO-liver
mice regardless of treatment—PBS or EGF-SubA (Fig. 4f, g, row
a, lanes 1–4 vs. lanes 5–8; Supplementary Fig. 8). There was no
difference between the livers of EGF-SubA-challenged
fortilinKO-liver and fortilinWT-liver mice in the levels of P-PERK,
PERK, P-eIF2α, eIF2α, and ATF6f (Fig. 4f, IB and the bottom
graph). In contrast, the phosphorylation of IRE1α (Fig. 4g, bands
b2, b3, and b4 vs. bands b6, b7, and b8, and also the bottom
graph) and JNK (Fig. 4g, bands d2, d3, and d4 vs. bands d6, d7,
and d8, and also the bottom graph; and Supplementary Fig. 4E for
ELISA of JNK and P-JNK) in the liver was more extensive in
EGF-SubA-treated fortilinKO-liver mice than in EGF-SubA-treated
fortilinWT-liver mice. The processing of XBP1 into the active form
XBP1s by P-IRE1α was also greater in the livers of fortilinKO-liver
mice than in those of fortilinWT-liver mice (Fig. 4h, lanes 2–6 vs.
lanes 8–12 for EGF-SubA-treated fortilinWT-liver and
fortilinKO-liver mice, respectively, also the bottom graph).
Because XBP1s, a transcriptional factor, induces genes involved
in ER-associated degradation (ERAD)9, we tested whether Edem1
and Herp1—ERAD genes—are induced more robustly in the
livers of fortilinKO-livermice than in fortilinWT-liver mice in
response to EGF-SubA challenge. We performed quantitative
reverse transcription polymerase chain reaction (RT-qPCR) on
the total liver RNA and found that both Edem1 and Herp1 were
induced more in the livers of EGF-SubA-treated fortilinKO-liver
mice than in those of EGF-SubA-treated fortilinWT-liver mice
(Fig. 4i).
Hematoxylin and eosin (H&E) staining of SubA-treated liver
sections also showed more drastic histopathological changes in
fortilinKO-liver mice than in fortilinWT-liver mice (Supplementary
Fig. 4F, total injury score= 17 vs. 14, respectively). Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining of the liver sections showed that the livers
of fortilinKO-liver mice challenged by EGF-SubA exhibited a
higher degree of apoptosis than those of fortilinWT-liver mice
(Fig. 4j, TUNEL; ***P< 0.005 by two-tailed unpaired t-test).
Consistent with the immunoblot analysis results (Fig. 4g, rows b
and d), immunostaining showed higher levels of P-IRE1α and
P-JNK in the livers of fortilinKO-liver mice than in those of
fortilinWT-liver mice upon EGF-SubA challenge (Fig. 4j, P-IRE1α,
P-JNK; ***P< 0.005 by two-tailed unpaired t-test). TUNEL
positivity and the immunoreactivity of P-IRE1α and P-JNK in the
PBS-treated livers of fortilinKO-liver and fortilinWT-liver mice were
equally low (Supplementary Fig. 4G). These data suggest that
fortilin in the liver protects whole animals against ER stress-
induced liver damage and death by mitigating the activation of
the IRE1α stress sensing pathway and hepatocyte apoptosis.
Fortilin blocks apoptosis in the liver by inhibiting IRE1α. We
demonstrated that the lack of fortilin in the liver sensitizes
hepatocytes to EGF-SubA-induced, ER stress-mediated activation
of IRE1α pathway (as evidenced by the phosphorylation of both
IRE1α and JNK, Fig. 4g, rows b and d) and apoptosis (as evi-
denced by increased TUNEL positive hepatocytes, Fig. 4j).
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Because fortilin is an anti-apoptotic protein16, 20–22, however, we
still do not know whether the apoptosis of fortilin-deficient
hepatocytes is the result of (i) EGF-SubA-induced hyperactivation
of the IRE1α pathway in the absence of fortilin or (ii) activation
of other apoptotic pathways that are normally and negatively
regulated by fortilin. To evaluate the exact role of fortilin in EGF-
SubA-induced ER stress-mediated liver damage, we repeated the
same experiment in the presence of the specific IRE1α inhibitor
KIRA644 (Fig. 5a). KIRA6 (CAS Registry Number = 1589527-65-0,
MW= 518.5) is an imidazopyrazine-based small-molecule IRE1α
inhibitor that competitively binds the ATP binding site of the
kinase domain (Fig. 3c) and blocks both the kinase and RNase
activities of the molecule45. We pretreated fortilinWT-liver and
fortilinKO-liver mice with KIRA6 for 3 days, injected EGF-SubA
(250 µg kg−1 body weight) once intraperitoneally on the third day,
continued KIRA6 treatment for another 6 days, sacrificed the
animals on the ninth day, and subjected the blood to CMP and
complete blood count (CBC) and the livers to histological and
molecular analyses. All animals survived for 9 days. Consistent
with data shown in Fig. 4d, when treated with the vehicle (not
KIRA6), fortilinKO-liver mice showed a drastically higher elevation
of ALT than did fortilinWT-liver mice (Fig. 5b, Vehicle). When
treated with KIRA6, however, neither the ALT (Fig. 5b, KIRA6)
nor the ALP/TBIL (Supplementary Fig. 5) levels of EGF-SubA-
challenged fortilinKO-liver mice were statistically significantly
different from those of fortilinWT-livermice. There was no sig-
nificant difference in H/H or WBC counts between EGF-SubA-
challenged fortilinWT-liver and fortilinKO-liver mice, regardless of
KIRA6 treatment (Supplementary Table 3). Upon gross inspec-
tion, the livers of fortilinKO-liver mice appeared similar to those of
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Fig. 5 Protection by fortilin against EGF-SubA-induced liver damage is mediated by its ability to block the activation of the IRE1α-JNK apoptosis pathway.
a Experimental protocol. Five-week-old male fortilinWT-liver or fortilinKO-liver mice (n= 6) were pretreated by vehicle or the IRE1α kinase inhibiting RNAse
attenuator-6 (KIRA6) for 3 days, challenged by EGF-SubA once on the third day, and treated by vehicle or KIRA6 for an additional 6 days. b KIRA6 protects
both fortilinWT-liver and fortilinKO-liver mice against EGF-SubA-induced liver damage. The sera from EGF-SubA-challenged fortilinWT-liver and fortilinKO-liver
mice, treated with either vehicle or KIRA6, were assayed for ALT. Data were expressed as means± s.d. (n= 6) and analyzed by two-tailed unpaired t-test.
NS not statistically significant; ***P< 0.005. c The livers of EGF-SubA-challenged fortilinWT-liver and fortilinKO-liver mice exhibit similar gross appearance
when treated with KIRA6. Scale bar= 10mm. d Lack of change in expression and phosphorylation patterns of the PERK and ATF6 pathway proteins in the
EGF-SubA-challenged livers, regardless of the status of fortilin or of KIRA6 treatment. The total lysates from the livers of EGF-SubA-challenged
fortilinWT-liver and fortilinKO-liver mice, treated with either KIRA6 or vehicle, were subjected to quantitative IB using the indicated antibodies. Data were
expressed as means± s.d. (n= 4) and analyzed by two-tailed unpaired t-test. e The livers of EGF-SubA-challenged fortilinWT-liver and fortilinKO-liver mice
exhibit a similar degree of IRE1α and JNK phosphorylation when treated with KIRA6. Data were expressed as means± s.d. (n= 4) and analyzed by
two-tailed unpaired t-test. *P< 0.05; ***P< 0.005. f The livers of EGF-SubA-challenged, KIRA6-treated, fortilinWT-liver and fortilinKO-liver mice exhibit a
similar degree of XBP1 splicing. The total RNA from the livers of EGF-SubA-challenged fortilinWT-liver and fortilinKO-liver mice were assayed for the amounts
of XBP1s and XBP1u. Data were expressed as means± s.d. (n= 4) and analyzed by two-tailed unpaired t-test. ***P< 0.005. g The livers of
EGF-SubA-challenged fortilinWT-liver and fortilinKO-liver mice exhibit equal amounts of apoptosis when treated with KIRA6. Paraffin sections from the livers
of EGF-SubA-treated fortilinWT-liver and fortilinKO-liver mice (n= 6 each) for cleaved lamin. Data were expressed as means± s.d. (n= 6) and analyzed by
two-tailed unpaired t-test. **P< 0.01; F.C. fold change. Scale bar= 50 µm. h, i The immunostaining of the livers of EGF-SubA-challenged fortilinWT-liver and
fortilinKO-liver mice exhibit the same degree of IRE1α pathway activation when treated with KIRA6. Data were expressed as means± s.d. (n= 6) and
analyzed by two-tailed unpaired t-test. ***P< 0.005. Scale bar= 50 µm. j Proposed model of the role of fortilin in ER stress-induced apoptosis
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fortilinWT-liver mice when treated with KIRA6 (Fig. 5c, KIRA6).
Mechanistically, KIRA6 treatment did not change the way the
PERK and ATF6 pathways responded to EGF-SubA in the pre-
sence and absence of fortilin in the liver (Fig. 5d; Supplementary
Fig. 8). Although IRE1α was more phosphorylated in the livers of
vehicle-treated fortilinKO-liver mice than in those of vehicle-
treated fortilinWT-liver mice (Fig. 5e, bands b3 and b4 vs. bands b1
and b2, respectively; Supplementary Fig. 8), the degree of the
phosphorylation of IRE1α in the livers of KIRA6-treated
fortilinKO-liver mice was similar to and as low as that in the
livers of KIRA6-treated fortilinWT-liver mice (Fig. 5e, bands b7 and
b8 vs. b5 and b6, respectively). In addition, although JNK was more
phosphorylated in the livers of vehicle-treated fortilinKO-liver mice
than in those of vehicle-treated fortilinWT-liver mice (Fig. 5e,
bands d3 and d4 vs. bands d1 and d2, respectively), the degree of
the phosphorylation of JNK in the livers of KIRA6-treated
fortilinKO-liver mice and was similar to that in the livers of
KIRA6-treated fortilinWT-liver mice (Fig. 5e, bands d7 and d8 vs.
d5 and d6, respectively). Further, when treated with KIRA6, the
processing of XBP1 into the active form XBP1s was no longer
significantly different between fortilinWT-liver and fortilinKO-liver
mice (Fig. 5f, lanes 9–12 vs. lanes 13–16; also the right panel).
Moreover, when treated with KIRA6, the livers of fortilinKO-liver
mice challenged by EGF-SubA exhibited the same degree of lamin
cleavage (i.e., apoptosis) as those of fortilinWT-liver mice (Fig. 5g).
Finally, consistent with these immunoblot analysis results
(Fig. 5e, rows b and d), immunostaining showed the same levels
of P-IRE1α and P-JNK in the livers of fortilinKO-liver mice and
fortilinWT-liver mice when the EGF-SubA-challenged mice were
treated with KIRA6 (Fig. 5h, i). Taken together, these data suggest
that fortilin blocked the majority of EGF-SubA-mediated liver
damage—as evidenced by elevated ALT (Fig. 5b), ALP (Supple-
mentary Fig. 5), and TBIL (Supplementary Fig. 5) levels—and
apoptosis (Fig. 5g) through its specific inhibition of the IRE1α
pathway.
Discussion
The current work reveals yet another facet of the anti-apoptotic
activity of fortilin. Previous studies have shown that fortilin exerts
its anti-apoptotic activity through (a) its binding to and stabili-
zation of MCL121, a BCL-2 family member and macrophage
survival factor46, (b) binding to and de-stabilization of trans-
forming growth factor-β-stimulated clone-22 (TSC-22), a pro-
apoptotic protein47, (c) binding to Ca2+ and blockade of Ca2
+-dependent apoptosis48, and (d) binding to and inhibition of the
tumor suppressor protein p5322. Based on the current work, we
now know that fortilin also inhibits apoptosis by directly inter-
acting with IRE1α in its cytosolic domain and blocking the
activation of its downstream pathways—XBP1 and JNK (the
latter leading to apoptosis). Importantly, fortilin selectively blocks
the IRE1α pathway without affecting the PERK and ATF6
pathways (Figs. 2d–f, 4f–h, and 4j). Our current working model is
as follows (Fig. 5j): Upon ER stress, IRE1α molecules,
unphosphorylated and monomeric at the baseline2, form clusters
with each other and start to trans-autophosphorylate each other2.
As soon as IRE1α becomes phosphorylated (P-IRE1α), fortilin
strongly binds to it (Fig. 3a, b, d, e, and Supplementary Fig. 3A)
and prevents it from phosphorylating other IRE1α molecules
(Fig. 2e, row b; Fig. 3l; Supplementary Fig. 3F; Fig. 4g, row b;
Fig. 4j, P-IRE1α; Fig. 5e, row b). The fact that fortilin binds
P-IRE1α (Fig. 3a, the right panel, lanes 3 and 4; Fig. 3e) and not
IRE1α (Fig. 3a, the right panel, lanes1 and 2; Fig. 3d) does not
necessarily contradict the fact that fortilin decreases IRE1α
phosphorylation, because P-IRE1α is the very kinase that phos-
phorylates IRE1α (trans-autophosphorylation). P-IRE1α, which is
the activated form of IRE1α, activates both the JNK apoptosis
pathway (Fig. 2e, row d) and the XBP1 pathway (Fig. 2e, row f;
Fig. 2f) in a dose-dependent fashion. Importantly, our molecular
docking data (Fig. 3i, j) suggest that the binding of fortilin to
P-IRE1α prevents the molecule from gaining access to and
phosphorylating the other IRE1α, as fortilin obliterates the kinase
core of the activated P-IRE1α (Fig. 3i). The MD simulation data
(Fig. 3j) support the notion that fortilin preferentially binds to
P-IRE1α because the fortilin–P-IRE1α complex is more thermo-
dynamically stable than the fortilin–IRE1α complex.
The UPR is designed to achieve two distinct biological goals: (i)
the preservation of stressed cells through restoration of ER
homeostasis and (ii) the elimination of afflicted cells through
apoptosis when they are damaged beyond repair. No ER stress
trigger is known to exert either homeostatic or apoptotic UPR
alone49. Rather, ER stress activates all UPR signaling pathways
and simultaneously produces both homeostatic and apoptotic
outputs49. How does fortilin participate in a life-or-death decision
of ER-stressed cells whose IRE1α pathway is activated? Because
fortilin negatively regulates both JNK (pro-apoptotic) and XBP1
(ER homeostasis, pro-survival) pathways through its binding to
and inhibition of P-IRE1α (Fig. 5j), the anti-apoptotic activity of
fortilin could be overcome by its inability to mount sufficient pro-
survival signals, leading to apoptotic death of the cells. Experi-
mentally, however, fortilin consistently protected the cells
(Fig. 1c–h, Supplementary Fig. 1D, E, Fig. 4j [TUNEL], and 5g)
against apoptosis. A hint may lie in the fact that XBP1 mRNA
splicing activity is only transiently activated in the early phase of
the UPR49, 50 and that fortilin is gradually induced by various
stresses—such as high concentration glucose51, heat52, and ROS53
—and remains upregulated for a longer duration than does XBP1
mRNA splicing activity. In the early phase of the UPR when
fortilin exists at a lower concentration in the cell, the XBP1
pathway might promote cell survival by restoring its homeostasis.
In the late phase of the UPR when the XBP1 mRNA splicing
activity subsides49, 50, fortilin might sustain cell survival by
blocking the JNK pro-apoptotic pathway. Further investigation is
needed to understand how fortilin navigates the dichotomy
between JNK-induced apoptosis and XBP1-mediated homeostasis
and survival.
Although many proteins interact with IRE1α42 (Supplementary
Fig. 3G), only three are known to bind IRE1α and negatively
regulate the IRE1α pathway aside from fortilin. They are BAX
inhibitor 1 (BI-1, also known as transmembrane Bax inhibitor
motif containing 6 [TMBIM6])54, Jun activation domain-binding
protein-1 (JAB1, also known as CSN5 and COPS5)55, and
receptor for activated C-kinase 1 (RACK1, also known as guanine
nucleotide binding protein, beta polypeptide 2-like 1 [GNB2L1])56
(Supplementary Fig. 3G,*). BI-1 is a 295-aa transmembrane
protein that binds to the cytosolic portion of IRE1α and inhibits
the processing of XBP1 mRNA. JAB1, a 334-aa protein with a
nuclear localization signal, binds to the linker region of the
cytosolic portion of IRE1α in the absence of stress. Upon ER
stress, JAB1 dissociates from IRE1α, allowing IRE1α to splice
XBP1 mRNA into XBP1s, suggesting that JAB1 inhibits IRE1α
through its binding55. It is unknown how the association between
JAB1 and IRE1α is regulated or whether JAB1 prevents the kinase
activity of IRE1α. RACK1, a 317-aa scaffold protein containing
seven Trp-Asp 40 repeats, binds to the linker region of IRE1α56.
RACK1 also binds to protein phosphatase 2A (PP2A), positions
IRE1α and PP2A close to each other, and keeps IRE1α depho-
sphorylated and inactivated56. ER stress increases the association
between RACK1 and IRE1α, and PP2A dissociates from RACK1
under ER stress, facilitating autophosphorylation and activation
of IRE1α56. In the current work, we found that fortilin, a 172-aa
protein with no homology to BI-1, JAB1, or RACK1, also binds to
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the cytosolic portion of IRE1α. Unlike JAB1, which dissociates
from IRE1α in response to ER stress, fortilin translocates from the
nucleus to the cytosol upon ER stress, gains access to the cytosolic
portion of IRE1α (Fig. 1a and Supplementary Fig. 1A),
and preferentially binds to P-IRE1α (Fig. 3a, e, j). There, unlike
BI-1, JAB1, or RACK1, fortilin uniquely inhibits both the
kinase (Fig. 2e, row d; Figs. 3l and 4g, row d; Fig. 4j, P-JNK;
Supplementary Figs. 2 and 4E) and RNase (Fig. 2e, row f; Figs. 2f,
3k, 4h, i) activities of IRE1α.
Rapidly growing tumors may outgrow their vascular supply
and experience hypoxia and hypoglycemia2. For tumor cells to
adapt to and survive in this adverse microenvironment, activation
of the UPR is crucial57. In fact, the activation of IRE1α has been
shown to facilitate angiogenesis and invasion of cancerous cells58.
Fortilin, an inhibitor of activated IRE1α (Fig. 5j) may inhibit
IRE1α-mediated tumor growth and invasion in certain tumors.
There has been no effort made to test whether fortilin is mutated
and made dysfunctional in certain tumors. It is possible that
certain fortilin mutations could make fortilin unable to bind
IRE1α, thus activating the XBP1 homeostasis branch of the IRE1α
pathway and facilitating tumor growth and propagation. In
contrast, other tumors could take advantage of wild-type fortilin
to block the activation of the IRE1α-JNK apoptosis pathway to
survive and propagate.
Hepatocytes, which produce and secrete a large amount of
proteins, are naturally susceptible to ER stress. ER stress has been
shown to contribute to various liver diseases59. Results of the
current study show that the lack of fortilin made the liver unu-
sually susceptible to ER stress-induced dysfunction and injury
(Figs. 4 and 5 and Supplementary Figs. 4 and 5). It is likely that
fortilin would fortify the liver against ER stress-induced and
IRE1α-mediated liver injury, which is known to occur in alcoholic
liver disease60 and viral hepatitis61.
Further studies are needed to therapeutically exploit the newly
unraveled physical and functional interaction between fortilin
and IRE1α in human diseases. The fortilinflox/flox mice described
herein (Supplementary Fig. 4A, B) should be a viable translational
tool to evaluate the role of fortilin and the fortilin-IRE1α inter-
action in handling stress in a tissue-specific fashion.
Methods
Molecular cloning. For cloning of fortilin complementary DNA (cDNA) into the
pESG-IBA5-vector, the cDNA encoding human fortilin obtained previously in our
laboratory16 was cloned into the multiple cloning site of the pESG-IBA5 mam-
malian expression vector (IBA Life Sciences, Göttingen, Germany) using a PCR-
based strategy.
Cell culture and cell lines. Both U2OS (Catalog #: HTB-96) and PC3 (Catalog #:
CRL-1435) cell lines were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). These cell lines were maintained in high-glucose
Dulbecco’s modified Eagle’s medium and Roswell Park Memorial Institute (RPMI)
1640 medium, respectively, and supplemented with 10% fetal bovine serum (FBS)
(HyClone, Logan, UT, USA) at 37 °C in an atmosphere containing 5% CO2.
MycoFluor™ (ThermoFisher Scientific-Molecular Probe, Eugene, OR, USA) was
used to detect mycoplasma contamination when appropriate.
U2OS cells stably overexpressing fortilin (U2OSFortilin-HA) or influenza
hemagglutinin (HA) epitope-tag sequence YPYDVPDYA only (U2OSEmpty-HA)
were generated as described previously62. To generate the fortilin-deficient and
control PC3 cell lines (PC3sh-Fortilin and PC3sh-Empty), PC3 cells were transduced
with the lentiviral particles containing the short hairpin RNA (shRNA) against
human fortilin (Lentivirussh-Fortilin) and Lentivirussh-Empty, which were generated,
according to the manufacturer’s instructions, from the pLKO.1-puro vector
containing the shRNA against human fortilin (pLKO.1-puro-sh-Fortilin) and the
empty shRNA sequence (pLKO.1-puro-sh-Empty) (Sigma-Aldrich, St Louis, MO,
USA), respectively, selected under puromycin (2.5 μg mL−1), and characterized by
immunoblot analysis. The cell lines were maintained in RPMI supplemented with
10% FBS and puromycin (2.5 µg mL−1, Mediatech, Inc., Manassas, VA, USA).
Immunoblot analyses. SDS-PAGE and immunoblot analyses were performed as
described previously34. The following primary antibodies were used at the
indicated dilutions/concentrations: Mouse anti-ATF6 (dilution used = 1:250, Clone
70B1413.1, Imgenex-Novus Biologicals, Littleton, CO, USA); Mouse anti-α-tubulin
(dilution used = 1:250, Clone B-7, Santa Cruz Biotechnology, Dallas, TX, USA);
Mouse anti-β-actin (dilution used = 1:250, Clone C4, Santa Cruz Biotechnology);
Goat anti-calnexin (dilution used= 1:250, sc-6465, Santa Cruz Biotechnology);
Rabbit anti-calreticulin (dilution used = 1:1000, Clone D3E6, #12238, Cell Signal-
ing Technologies, Danvers, MA, USA); Rabbit anti-caspase-3 (dilution used=
1:1000, Clone 8G10, Cell Signaling Technologies), which was used to detect full-
length, p17, and p19 caspase-3; Rabbit anti-caspase-9 (dilution used= 1:1000,
#9502, Cell Signaling Technologies), which was used to detect full-length and
cleaved caspase-9; Rabbit anti-cytochrome c (dilution used= 1:1000, Clone 136F3,
Cell Signaling Technologies); Rabbit anti-eIF2α (dilution used= 1:500, #9722, Cell
Signaling Technologies); Rabbit anti-phospho-human-eIF2α (dilution
used = 1:500, Ser51, #9721, Cell Signaling Technologies); Rabbit anti-phospho-
mouse-eIF2α (dilution used = 1:1000, Ser51, Clone D9G8, Cell Signaling Tech-
nologies); Mouse anti-fortilin (dilution used = 1:1000, Clone M03, Abnova, Taipei
City, Taiwan), which was used for all experiments other than those shown in
Supplementary Fig. 1A and Supplementary Fig. 1B; Rabbit anti-fortilin (dilution
used = 1:250, PM017, MBL International, Woburn, MA, USA), which was used for
the experiments depicted in Supplementary Fig. 1A and B; Rabbit anti-fortilin
monoclonal antibody (concentration used= 14 µg mL−1, Clone EPR5540,
ab133568, Abcam), which was used to immunoprecipitate fortilin, as shown in
Fig. 3b and Supplementary Fig. 3A; Mouse anti-GAPDH (dilution used = 1:10,000,
Clone 10R-G109a, Fitzgerald, Acton, MA, USA); Rabbit anti-GRP78 (dilution used
= 1:500, sc-13968, Santa Cruz Biotechnology); Mouse anti-HDAC2 (dilution used
= 1:1000, Clone Y461, Abcam); Rabbit anti-HSP60 (dilution used = 1:1000, Clone
D6F1, Cell Signaling Technologies); Rabbit anti-HSP90 (dilution used= 1:1000,
#4874, Cell Signaling Technologies); Rabbit anti-IRE1α (dilution used= 1:500,
sc-20790, Santa Cruz Biotechnology); Rabbit anti-phospho-IRE1α (dilution
used = 1:1000, ab48187, Abcam); Rabbit anti-JNK (dilution used = 1:500, sc-571,
Santa Cruz Biotechnology); Rabbit anti-phospho-human-JNK (dilution used= 1:500,
#9251, Cell Signaling Technologies); Rabbit anti-phospho-mouse-JNK (dilution
used = 1:250, 07-175, EMD Millipore, Billerica, MA, USA); Rabbit anti-cleaved
Lamin A (dilution used = 1:250, #2035, Cell Signaling Technologies); Rabbit
anti-MBP (dilution used = 1:500, sc-13914, Santa Cruz Biotechnology); Mouse
anti-NQO2 (dilution used = 1:250, Clone A-5, Santa Cruz Biotechnology); Rabbit
anti-PARP (dilution used = 1:1000, #9542, Cell Signaling Technologies), which was
used to detect full-length PARP; Rabbit anti-cleaved PARP (Asp214) (dilution used
= 1:1000, Clone D64E10, #5625, Cell Signaling Technologies); Rabbit anti-human-
PERK (dilution used= 1:500, #5683, Cell Signaling Technologies); Rabbit anti-mouse-
PERK (dilution used= 1:500, sc-13073, Santa Cruz Biotechnology); Mouse anti-
phosphoserine (dilution used= 1:1000, Clone 4A4, EMD Millipore); Rabbit anti-
XBP1 (dilution used= 1:500, sc-7160, Santa Cruz Biotechnology). All antibodies
were used with appropriate IRDye680LT- or IRDye800CW-conjugated secondary
antibodies (LI-COR, Lincoln, NE, USA). The signal intensities of protein bands
were quantified using the Odyssey Infrared Imaging System (LI-COR).
Subcellular fractionation. ER subcellular fractions were obtained from 1.5 × 106
PC3 cells treated with either 0.5 µM TG, 2 nM EGF-SubA, or dimethyl sulfoxide
(DMSO) using the Subcellular Protein Fractionation kit (Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions. Protein concentrations of each
fraction were determined using BCA methods (Bio-Rad, Hercules, CA, USA).
Exactly 10 μg of total proteins were resolved by 12% SDS-PAGE and subjected to
immunoblot analysis using anti-calreticulin (an ER marker63), anti-HSP90 (cytosol
marker64), HDAC2 (a nuclear marker65), and anti-fortilin antibodies.
DNA fragmentation assay. The Cell Death Detection ELISA PLUS kit (Roche,
Indianapolis, IN, USA) was used following the manufacturer’s instructions, with
modifications described previously22. For Fig. 1c, d, PC3sh-Fortilin or PC3sh-Empty
cells (0.3 × 106 per well) were seeded into six-well plates. The next morning, cells
were treated with various concentrations of TG (0, 0.5, and 1.0 µM) or EGF-SubA
(0.2, 2, and 20 nM, SibTech, Brookfield, CT, USA) for 24 h before they were
harvested (both adherent and floating) and subjected to the same assay22. For
Supplementary Fig. 1D, U2OSEmpty-HA or U2OSFortilin-HA cells (0.3 × 106 per well)
were seeded into six-well plates. The next morning, cells were treated with DMSO
or 0.5 µM TG for 24 h before they were harvested (both adherent and floating) and
subjected to the assay22.
Flow cytometric analysis of apoptotic and necrotic cells. To assess the relative
contribution of apoptosis and necrosis to total cell death induced by TG and EGF-
SubA, PC3 cells were stained with FITC-conjugated Annexin V and PI (1 µg mL−1)
and subjected to flow cytometry analysis per the manufacturer’s instructions
(ThermoFisher-Invitrogen-Molecular Probes). The population separated into four
groups: (i) live cells without apoptosis or necrosis (no red or green fluorescence),
(ii) apoptotic cells without necrosis (positive green fluorescence and negative red
fluorescence), (iii) necrotic cells without apoptosis (negative green fluorescence and
positive red fluorescence), and (iv) cells exhibiting both necrosis and apoptosis
(positive green and red fluorescence). Flow cytometry data are represented as
mean± s.d. of four independent experiments.
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Cytochrome c release assay. The cytosolic and membrane fractions from PC3sh-
Fortilin and PC3sh-Empty cells stimulated by 1.0 µM and 20 nM of TG and EGF-SubA,
respectively, for 24 h were obtained using the Subcellular Protein Fractionation Kit
for cultured cells (Catalog #: 78840, ThermoFisher Scientific) according to the
manufacturer’s instructions. Fifty microgram of cytosolic and membrane
(mitochondrial) fraction protein extracts were loaded onto each lane of a 12%
SDS-polyacrylamide gel, separated, and blotted to nitrocellulose membranes, which
were probed by anti-cytochrome c antibody, anti-HSP90 (cytosolic marker
protein64), and anti-HSP60 (mitochondrial marker protein64).
Immunocytochemistry of fortilin and the ER marker protein disulfide
isomerase (PDI). Immunocytochemical analyses to determine subcellular locali-
zation of fortilin under ER stress were performed using the SelectFX Alexa Fluor
488 Endoplasmic Reticulum Labeling kit (Molecular Probes) as previously
described16. U2OS cells were seeded on a cover glass, fixed in 4% buffered formalin
solution for 5 min, permeabilized in 0.2% Triton X, and incubated with rabbit
anti-fortilin (MBL International) and mouse anti-PDI (Molecular Probes) anti-
bodies. After washes, bound antibodies were detected with goat anti-rabbit
AlexaFluor® 568-conjugated and goat anti-mouse AlexaFluor® 488-conjugated
(Invitrogen, Grand Island, NY, USA) secondary antibodies, respectively. 4′,6-dia-
midino-2-phenylindole (DAPI, Sigma-Aldrich) was used to counterstain the
nuclear DNA. The stained slides were examined under a fluorescence microscope
(Eclipse Ti, Nikon Inc., Melville, NY, USA) with appropriate filter sets. The extent
of fortilin recruitment to the ER was quantified by counting cells (at least 50) and
determining the percentage of cells that exhibit co-localization of AlexaFluor® 568
and AlexaFluor® 488 signals; results are expressed as % co-localization (Supple-
mentary Fig. 1A).
MTT cell survival assay. The assay was performed as previously described66.
U2OSEmpty-HA or U2OSFortilin-HA cells were plated in 96-well plates (1 × 104 cells
per well). The next day, cells were challenged with either 0.5 µM TG or DMSO,
treated with 10 µg mL−1 of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, Sigma-Aldrich) for 4 h, and solubilized by solubilization buffer
(10% SDS in 0.01 N HCl) overnight. Formed MTT formazan was quantified by
measuring the absorbance of each well at 600 nm (A600) using a SpectraMax
spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). The cell survival
rate was quantified as follows: (A600 of treated cells−A600 of background)/(A600 of
untreated cells–A600 of background) × 100; results are expressed as arbitrary units
(A.U.) (Supplementary Fig. 1C).
Caspase activity assays. Assays to measure caspase-3, -8, and -9 activities of
U2OSEmpy-HA and U2OSFortilin-HA cells treated for 6 h with either DMSO for TG
were performed as described previously16 and using fluorometric assay kits
according to the manufacturer’s instructions (Biovision, Mountain View, CA,
USA).
XBP splicing assay. Analysis of XBP1 splicing as a surrogate marker of IRE1α
activation was performed as previously described67. Briefly, first-strand cDNA was
synthesized from the total RNA isolated from PC3 cells (Fig. 2f) or mouse livers
(Figs. 4h and 5f) using SuperScript III reverse transcriptase (Invitrogen). Because
activated IRE1α processes the XBP1 mRNA (XBP1u, 473 base pairs (bp)) to a
shorter XBP1 mRNA that lacks a 26 bp fragment including the PstI restriction site
(XBP1s, 447 bp), cDNA from the spliced form XBP1s is resistant to PstI, whereas
that from the unprocessed form XBP1u is digested by PstI into 290 and 183 bp
fragments. The cDNAs of XBP1u and XBP1s were amplified by PCR using the
same primer set: 5′-AAACAGAGTAGCAGCGCAGACTGC-3′ and 5′- TCCTT
CTGGGTAGACCTCTGGGAG -3′. The amplicons were digested by PstI, resolved
on 2% agarose gels containing ethidium bromide, and then visualized using the Gel
Doc XR + system (Bio-Rad). The 447 bp band represented the cDNA amplicon
from the processed XBP1s, whereas both the 290 and 183 bp bands originated from
the cDNA amplicon from the unprocessed XBP1u. The band density was quan-
tified using the Gel Doc™ XR + System (Bio-Rad), and results are expressed as A.U.
Enzyme-linked immunosorbent assay. Quantifications of total JNK and P-JNK in
EGF-SubA-challenged PC3sh-Fortilin and PC3sh-Empty cells as well as EGF-SubA-
treated livers of fortilinWT-liver and fortilinKO-liver mice were achieved using the
PathScan® Total SAPK/JNK Sandwich ELISA Kit and PathScan® Phospho-SAPK/
JNK (Thr183/Tyr185) Sandwich ELISA Kit, respectively (Cell Signaling Technol-
ogy). For the cell-based assay, PC3sh-Fortilin and PC3sh-Empty cells were plated into
six-well plates (0.3 × 106 cells per well), treated with EGF-SubA (0–20 nM, Sib-
Tech) for 24 h, and subjected to ELISA. For the whole animals, fortilinWT-liver, and
fortilinKO-liver mice were intraperitoneally administered 250 µg kg−1 body weight of
EGF-SubA and sacrificed on day 7. The total lysates from the livers were then
subjected to ELISA according to the manufacturer’s instructions.
Proximity ligation assay. PLA was originally described by Soderberg et al.31.
Wild-type PC3 cells were seeded on a chamber slide, treated with either PBS or
2 µM EGF-SubA (SibTech), fixed in 10% buffered formalin solution, permeabilized
in 0.1% Triton X, and incubated with (a) mouse anti-fortilin (2C4, Abnova) and (b)
either rabbit anti-IRE1α (Santa Cruz Biotechnology) or rabbit anti-phospho-IRE1α
(Abcam) antibodies. The chamber slide was then incubated for 1 h with secondary
anti-mouse and anti-rabbit antibodies conjugated to oligonucleotides (PLA probes
MINUS and PLUS, Duolink In Situ Proximity Ligation Assay, Sigma-Aldrich)
before ligase and two connector oligonucleotides were added to the solution. These
oligonucleotides hybridize to the two PLA probes and join them into a closed circle
if they are in close proximity (about 30 nm). Subsequently, fluorescently labeled
oligonucleotides that hybridized to the rolling circle amplification product were
added. The nuclei were stained with DAPI. A Zeiss LSM 510 Meta confocal
microscope system (Oberkochen, Germany) was used to visualize the signals. The
PLA Interaction Index was calculated by dividing the number of red dots by the
number of nuclei as stained by DAPI; results are expressed as A.U.
Immunoprecipitation and co-immunoprecipitation. Cleared total cell lysates
from PC3 cells treated with 2 nM EGF-SubA for 24 h were incubated with either
rabbit monoclonal anti-fortilin antibody (Clone EPR5540, Abcam) or rabbit IgG.
Formed protein–antibody complexes were precipitated by Dynabeads™ Protein G
(Dynal-ThermoFisher Scientific), washed four times, eluted into SDS gel loading
buffer; and subjected to SDS-PAGE, immunoblot transfer, and immunodetection.
Successful immunoprecipitation of fortilin was confirmed using anti-fortilin (M03,
Abnova) antibody, whereas anti-IRE1α, anti-P-IRE1α, anti-β-actin, and anti-α-
tubulin antibodies were used to detect co-immunoprecipitated IRE1α, P-IRE1α,
β-actin, and α-tubulin, respectively. Both β-actin and α-tubulin have been shown to
interact with fortilin32, 33. NQO2, a protein that is known not to interact with
fortilin34, was used as negative control to ensure that sufficient washing to elim-
inate non-specific bindings occurred. Rabbit IgG was used to rule out the non-
specific interaction that withstood the wash conditions used in the protocol.
Generation of recombinant human fortilin. Affinity purification of human
recombinant fortilin was performed using the Strep-tag purification system (IBA
Life Sciences) as described previously68. 293T cells stably expressing human fortilin
tagged with the Strep-tag II (WSHPQFEK) at its N-terminal end were collected
by trypsinization, washed in PBS, resuspended in buffer W (100 mM Tris HCl
[pH = 8], 150 mM NaCl, 1 mM EDTA), lysed by repeated freeze-thaw cycles, and
sonicated to shear the genomic DNA. Cleared total cell lysate was then passed
through a column packed with Strep-Tactin-Superflow resin (IBA Life Sciences).
The column was washed five times with Buffer W before the Strep-tagged fortilin
was eluted with Buffer E (Buffer W plus 2.5 mM desthiobiotin). The fractions were
pooled and concentrated using centrifugal filters (Amicon® EMD Millipore). The
concentrated protein samples were buffer-exchanged into PBS using Zeba™ Spin
Desalting Columns (ThermoFisher Scientific). The final purification product was
characterized by Coomassie and immunoblot analyses (Supplementary Fig. 3B,
lane 9; Supplementary Fig. 3F, fortilin).
Dephosphorylation of P-IRE1α. Dephosphorylation of recombinant P-IRE1α was
performed using calf intestinal alkaline phosphatase (CIP)-agarose beads according
to the manufacturer’s instructions (Sigma-Aldrich). Recombinant phospho-IRE1α
(0.4 μg protein per sample, Origene, Rockville, MD, USA) was resuspended in
reaction buffer (50 mM Tris HCl, 10 mM NaCl, 1 mM MgCl2, 0.1 mM
dithiothreitol (DTT), pH 7.9) and treated with CIP-agarose (1 unit of CIP per
0.4 μg of protein) at 37 °C for 2 h. The reaction was stopped by separating the
bead-bound enzyme from the reaction mixture by centrifugation at 1902 × g. The
CIP-treated sample was subjected to immunoblotting using rabbit anti-phospho
IRE1α antibody (Abcam) (Supplementary Fig. 3E).
Bio-layer interferometry. Recombinant human fortilin protein produced as
described above was biotinylated and immobilized on streptavidin-coated bio-
sensors (ForteBio, Menlo Park, CA, USA) at a concentration of 25 μg mL−1 for
600 s, followed by buffer exchange in PBS. The system was tested using anti-fortilin
antibody (positive control, Abnova) and bovine serum albumin (negative control,
Sigma-Aldrich) as depicted in Supplementary Fig. 3C, D. Next, various con-
centrations of recombinant human phopho-IRE1α-Myc-DDK (aa 1–977, Origene),
de-phosphorylated IRE1α-Myc-DDK (aa 1–977, Origene, see above for the
dephosphorylation procedure), GST-IRE1α-L (aa 1–70, Abnova), GST-IRE1α-TM
(aa 401–500, Abnova), and GST-IRE1α-C (aa 468–977, SignalChem, Richmond,
British Columbia, Canada) were added for 180 s to evaluate the association between
the two molecules. The integrity of these recombinant proteins was evaluated by
SDS-PAGE and Coomassie staining (Supplementary Fig. 3B, lanes 2, 5, 6, 7, and 9).
Finally, the reaction mixture was replaced with PBS for 300 s to evaluate the
dissociation. The binding data were processed and the dissociation constant (Kd)
was calculated using BLItz analysis software (ForteBio). The data depicted in
Fig. 3d–h and Supplementary Fig. 3C, D represent the results of three independent
binding experiments.
Molecular docking assay of fortilin and IRE1α. To study how fortilin and IRE1α
interact with each other, we performed a molecular docking experiment using
Piper software on the ClusPro Server 2.069 and the crystal structures of fortilin
(2HR9) and IRE1α (4U6R) available from the Protein Data Bank70. We evaluated
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docking results using clustering analysis and weighted model scores as described by
Kozakov et al.71 From the top 10 cluster populations, we selected the binding pose
that yielded the best average cluster weighed score and used it for the determi-
nation of binding free-energy by MD. For MD simulations, we used the Gromacs
v5.0.4 software package utilizing the GROMOS 54A7 force-field parameter set72.
We adopted force-field parameters for post-translational modification of phos-
phorylation from Hansson et al.73 and applied them to the GROMOS 54A7 force
field as previously described72. An initial 100 ns MD simulation of fortilin bound
with IRE1α was performed using the binding configuration obtained from the
protein-protein docking studies. Simulations were performed using periodic
boundary conditions with explicit solvation using a simple point charge model
potential. To prepare the system for simulation, a conjugate gradient energy
minimization followed by NVT (number of particle, volume, and temperature) and
NPT (number of particle, pressure, and temperature) equilibrations were per-
formed. A 100 ps equilibration was conducted under a NVT ensemble using a
v-rescale thermostat at 300 K with a coupling time constant of 0.1 ps. A subsequent
200 ps NPT equilibration was performed using the isotropic Parrinello-Rahman
barostat with a time constant of 1.0 ps. The integration time steps for both equi-
libration steps were 1 fs. The 100 ns MD simulation was executed using 2 fs time
steps. All bonds were constrained to equilibrium values using the LINCS algo-
rithm74. The Verlet cutoff scheme was used in calculation of short-range Coulomb
and van der Waals forces, and particle-mesh Ewald was used for long-range
electrostatics. The averaged structure over the final 10 ns was used in the sub-
sequent free-energy simulations. Phosphoserine groups were added to IRE1α at
S724 and S726, followed by energy minimization and equilibration of the system as
described above. To calculate the relative binding free energy of fortilin between
phosphorylated (P-IRE1α) and unphosphorylated IRE1α (IRE1α), the following
classic thermodynamic cycle was used:
IRE1α, Fortilin IRE1α:Fortilin
P-IRE1α, Fortilin P-IRE1α:Fortilin
ΔG1
ΔG3
ΔG4
ΔG2
where ΔG1 is the free energy change resulting from phosphorylation of IRE1α at
S724 and S726 (P-IRE1α) in the unbound state and ΔG2 is the free energy change
resulting from phosphorylation of IRE1α in a bound state with fortilin. ΔG3 and
ΔG4 are the free energies of binding of fortilin with IRE1α and P-IRE1α, respec-
tively. To determine the relative binding free energy of fortilin between phos-
phorylated and unphosphorylated IRE1α (ΔG3−ΔG4), the following relationship
can be used: ΔΔG=ΔG3−ΔG4=ΔG1−ΔG2. Free energy calculations were per-
formed to compute the free energy change due to phosphorylation of IRE1α in the
unbound and bound states, representing ΔG1 and ΔG2, respectively. Simulation of
IRE1α phosphorylation (and reverse simulation of dephosphorylation) was
implemented in two steps constituting three states: A, B, and C. State A represents
phosphorylated IRE1α, state B corresponds to an intermediate conformation for
which the partial charges on the phosphate moiety are set to zero, and state C
represents unphosphorylated IRE1α, where the partial charges and van der Waals
radii of the atoms of the phosphate moiety are set to zero. Calculations were
performed for λ values at non-equidistant nodes provided in Supplementary
Table 4. The partial charges of modified atoms were decreased from λ= 0 to λ= 1
through seven intermediate λ values. The van der Waals parameters were decreased
from λ= 0 to λ= 1 through seven intermediate steps. During decoupling of van der
Waals interactions, soft-core potential functions were applied with αLJ= 0.5 and λ
power dependency set to 1. At each λ value, simulations were performed for 500 ps
at 0.5 fs time steps. ∂H/∂λ was saved every 10 fs for post-processing and free-energy
calculations using Bennett’s acceptance ratio (BAR) perturbation method75. Only
the last 250 ps of each simulation were used for BAR calculations, the first 250 ps
being considered as additional system equilibration.
In vitro IRE1α RNase activity assay. The endoribonuclease (RNase) activity of
IRE1α in the presence of fortilin was assayed in vitro using fluorescence resonance
energy transfer (FRET)-based methods described previously39. Briefly, recombi-
nant human IRE1α (10 µg, SignalChem) was pre-incubated with various con-
centrations of recombinant human fortilin (0–4 µM) in RNase Assay Buffer
(50 mM HEPES, pH 7.2, 100 mM KOAc, 0.005% TritonX-100, 5 mM DTT, 5%
glycerol) for 30 min at room temperature. Next, 25 µl of 2 µM fluorescently tagged
XBP1 RNA stem loop (5′-FAM-CAGUCCGCAGCACUG-Iowa-Black-FQ-3′,
Integrated DNA Technologies, Coralville, IA, USA) were added to the reaction
mixture, which was then incubated for 90 min at room temperature. Fluorescence
was read using a SpectraMax M2e plate reader (Molecular Devices) with excitation
and emission at 495 and 520 nm, respectively.
In vitro IRE1α kinase activity assay. The kinase activity of IRE1α in the presence
of fortilin was assayed in vitro as previously described41 using (a) [γ-33P]ATP or
(b) anti-phosphoserine antibody as follows. First recombinant human IRE1α
(15 nM, SignalChem), MBP (20 µM, SignalChem), and various concentrations of
fortilin were prepared in kinase reaction buffer (20 mM HEPES, pH 7.5, 10 mM
MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mgmL−1 BSA, 0.1 mM Na3VO4, 2 mM
DTT, and 1% DMSO) and incubated for 20 min at room temperature. The reaction
was initiated by addition of [γ-33P]ATP (10 µM), carried out for 2 h at room
temperature, and terminated by spotting the reaction mixture onto phospho-
cellulose P81 ion exchange filter paper (GE Whatman, Pittsburgh, PA, USA). The
filter paper was washed three times with 1% phosphoric acid to remove unbound
phosphate, placed in a scintillation tube containing scintillation cocktail, and
subjected to scintillation counting. After subtracting background derived from
control reactions lacking the kinase, kinase activity data were expressed as the
percent kinase activity in test samples compared to reaction mixture with no
fortilin. The data from two independent experiments were interpolated to a sig-
moidal four parameter logistic curve, from which the half maximal inhibitory
concentration (IC50) of fortilin was derived (GraphPad Prism, La Jolla, CA, USA)
(Fig. 3l). For the further assessment of in vitro IRE1α kinase activity, recombinant
human IRE1α (0.5 µg, SignalChem) was pre-incubated with various concentrations
of recombinant human fortilin (0–4 µg) in Kinase Assay Buffer (25 mM MOPS pH
7.2, 12.5 mM β-glycerol-phosphate, 25 mM MgCl2,
5 mM EGTA, 2 mM EDTA, 0.25 mM DTT, 20 µM ATP) for 15 min at room
temperature, followed by the addition of 2 µg of MBP (SignalChem) as a universal
kinase substrate76 to the reaction mixture. The reaction mixture was incubated at
30 °C for 45 min and subjected to SDS-PAGE and immunoblot analysis using anti-
phosphoserine (EMD Millipore), anti-MBP (Santa Cruz), anti-fortilin (Abnova),
and anti-phospho-IRE1α (Abcam) antibodies. The phosphorylation index was
calculated by dividing the signal intensity of phosphorylated MBP by that of total
MBP; results are expressed as A.U. Two independent experiments were performed
with consistent findings (Supplementary Fig. 3F).
Generation of liver-specific fortilin knockout mice. Fortilinflox/flox mice—in
which the fortilin gene was flanked by the LoxP sequence to allow tissue-specific
deletion—were generated using the standard homologous recombination technique
as previously described77. First, a mouse BAC clone containing the full fortilin gene
was isolated from the C57BL/6J ES BAC clone library. A fortilin targeting vector
was constructed by subcloning (a) the 4.8 kilobase (kb) upstream genomic
sequence, (b) the 3.6 kb genomic DNA sequence containing all six fortilin exons
(exon 1–exon 6), and (c) the 3.2 kb downstream genomic DNA sequence into the
pVBFRTCKR targeting vector (Supplementary Fig. 4A, #2) that already contained
(a) two LoxP sequences, (b) a phosphoglycerate kinase promoter-driven neomycin
resistance gene flanked by two flippase recognition target sequences, and (c) the
thymidine kinase cassette. After extensive sequencing to verify the integrity of the
construct, the targeting vector was linealized by I-CeuI (R0699S, New England
BioLabs, Ipswich, MA, USA) and electroporated into C57BL6 embryonic stem cells
(ESCs). ESC clones that survived in neomycin-containing media were analyzed by
PCR and Southern blotting (using radioactive DNA probes 1 and 2 after NdeI
[R0111S, New England BioLabs] and NsiI [R0127S] digestion, respectively) for
successful homologous recombination (Supplementary Fig. 4B). Two mutated ESC
lines (B43 and B61) were microinjected into C57BL6 blastocysts, which were then
implanted in pseudopregnant host mice to obtain chimeric mice. Chimeric mice
were then crossed with C57BL6 mates, and their offspring were tested using
PCR-based methods for germline transmission. The resultants fortilinflox/flox mice
were fully in the C57BL/6J genetic background from the beginning. Fortilinflox/flox
mice were then crossed with a transgenic flipase strain to remove the neomycin
resistance gene cassette. For the generation of liver-specific fortilin KO mice,
fortilinfloxflox mice were crossed with C57BL/6J mice overexpressing the Cre
recombinase transgene under the control of albumin enhancer/promoter (Stock
#: 0003574, Jackson Laboratory, Bar Harbor, ME, USA) to generate liver-specific
deletion of fortilin. Because the expression levels of fortilin in the livers of the Alb-
Cre+/−fortilinflox/flox mice were found substantively lower than their control Alb-
Cre−/−fortilinflox/flox mice (Fig. 4a), we performed all subsequent experiments using
Alb-Cre+/−fortilinflox/flox (denoted fortilinKO-liver hereafter) mice, without having
to generate Alb-Cre+/+fortilinflox/flox mice. The actual production of fortilinKO-liver
and fortilinWT-liver (Alb-Cre−/−fortilinflox/flox) mice for the experiments was
achieved by mating Alb-Cre+/−fortilinflox/flox and Alb-Cre−/−fortilinflox/flox mice,
yielding fortilinKO-liver and fortilinWT-liver mice in a 1:1 ratio. Genotyping of for-
tilinKO-liver and fortilinWT-liver mice was performed on tail-derived genomic DNA
using standard PCR-based methods. The presence of the Cre recombinase trans-
gene was detected using the following primer sets: 5′-GCGGTC TGGCAG
TAAAAACTATC-3′ (Supplementary Fig. 4A, M1) and 5′-GTGAAACAGCA
TTGCTGTCACTT-3′ (Supplementary Fig. 4A, M2), where Alb-Cre+/− mice
yielded a 100 bp amplified fragment and Alb-Cre−/− mice yielded no amplicons.
The presence of the LoxP-fortilin-LoxP knock-in construct was verified using the
following primer sets: 5′-TGGACC CTGACTTTCATCACCTC-3′ (Supplementary
Fig. 4A, F1) and 5′-GTCATCTAACCTTACCCCAGTAAGC-3′ (Supplementary
Fig. 4A, F2), where fortilinflox/flox mice yielded a 405 bp fragment and wild-type
fortilin mice (fortilinWT/WT mice) yielded a 280 bp fragment.
Mouse model of ER stress-induced liver damage. For EGF-SubA treatment,
5-week-old male fortilinKO-liver and fortilinWT-liver mice were intraperitoneally
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administered either PBS or EGF-SubA (Sibtech). For survival analyses, mice were
kept on a 12 h dark–light cycle and had access to food and water ad libitum. They
were examined daily for their behavior and health. For the mechanism of action
(MOA) analyses, mice were sacrificed by CO2 inhalation and cervical dislocation
7 days after injection, and whole blood and organs were collected for further
analyses. There was no blinding performed. For KIRA6 treatment, 5-week-old male
fortilinKO-liver and fortilinWT-liver mice were intraperitoneally administered either
5 mg kg−1 KIRA6 (Catalog #: 532281, EMB Millipore) in solution made of 3%
ethanol, 7% Tween-80, 90% saline or the same solution without KIRA6 as vehicle
daily for 9 days. On day 3 of the experiment, mice were intraperitoneally injected
with 250 μg kg−1 of EGF-SubA (SibTech) once. Mice were examined daily for their
behavior and health for a total of 9 days before they were sacrificed. The whole
blood and organs were collected for further analyses (n= 4 each for immunoblot
and XBP splicing assays, n= 6 for CBC, CMP, and immunohistochemistry) as
described below. There was no blinding performed.
Whole-blood analyses. For the CMP and CBC, whole blood was sampled by
cardiocentesis using a 25-gauge needle immediately after euthanasia by CO2 and
cervical dislocation. The sample was transferred into Microtainer® tubes with
lithium heparin (BD Biosciences, Franklin Lakes, NJ, USA) by removing the needle
from the syringe, pouring the blood into the tube, and mixing it thoroughly with
the lithium heparin. The blood chemistry profile was obtained using the Com-
prehensive Diagnostic Panel rotors and the Vetscan VS2 (Abaxis, Union City, CA,
USA). The following blood chemistry parameters were assayed for each sample:
albumin (ALB), ALP, ALT, AMY, TBIL, BUN, total calcium (Ca2+), phosphorus
(PHOS), CRE, glucose (GLU), sodium (Na+), potassium (K+), total protein (TP),
and globulin (GLOB). The results are shown in Figs. 4d and 5b and Supplementary
Figs. 4D and 5. CBC was obtained using the HEMAVET 950FS Hematology
System (Drew Scientific, Dallas, TX, USA). The CBC results are shown in
Supplementary Tables 2 and 3.
Quantitative reverse transcription polymerase chain reaction. RT-qPCR was
performed as described previously22. Briefly, the livers of fortilinWT-liver and for-
tilinKO-liver mice were harvested into Tri-Reagent (Molecular Research Center,
Cincinnati, OH, USA). RNA was isolated in accordance with the manufacturer’s
instructions and treated with DNAse (ABI, Foster City, CA, USA). RT-qPCR was
performed in quadruplicate with exactly 50 ng of total RNA using the TaqMan®
RT-PCR kit (Applied Biosystems [ABI] at Life Technologies, Grant Island, NY,
USA) in the ABI Step One Plus Real-Time PCR system and the following primer
and probe sets (Integrated DNA Technologies): Mouse Edem1—forward: 5′-TCT
GGTTGATGCCTTGGATAC-3′, reverse: 5′-GACCTGGACTGTGGAATCTTT-3′,
probe 5′-FAM-CCGAGTTCC/ZEN/AGAAGGCAGTCAAGTT-IAbkFQ-3′ where
FAM= carboxyfluorescein, IAbkFQ = Iowa Black FQ, and ZEN™= an internal
quencher to enhance the quenching activity of the 3′ quencher Iowa Black FQ;
Mouse Herp1—forward: 5′-CACCTTGTGTGCAATGTGAAG-3′, reverse: 5′-CCA
GGATGCTGTGTCTGATT-3′, probe: 5′-FAM-AATGCCAGA/ZEN/AACCAGC
ACAAAGGG-IAbkFQ-3′; and Mouse 18S ribosomal RNA (rRNA)—forward:
5′-GCCGCTAGAGGTGAAATTCT-3′, reverse: 5′-TCGGAACTACGACGGTA
TCT-3′, probe: 5′-JOEN-ACCAGAGCG/ZEN/AAA GCATTTGCCAAG-IAb
kFQ-3′ where JOEN= 6-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein.
Hematoxylin and eosin staining. The formalin-fixed H&E sections of liver tissue
were evaluated on day 7 post-SubA challenge for histopathologic changes. The
various parameters assessed included steatosis (macro- and micro-vesicular),
apoptosis, mitosis, inflammation, pattern of injury (for example, zones 1, 2, or 3),
and markers of injury such as the presence of giant mitochondria or Mallory’s
hyaline. The sections (n= 6 each for SubA-treated fortilinWT-liver and
fortilinKO-liver mice; n= 3 for PBS-treated fortilinKO-liver mice; n = 2 for
PBS-treated fortilinWT-liver mice) were blindly evaluated by an experienced hepa-
topathologist, who graded the above features on a scale of 0 to 4. Apoptotic and
mitotic counts were assessed semi-quantitatively by counting the number per a
high-power field.
Immunohistochemistry. All immunostained sections were digitally imaged using a
Nikon CoolScope (Nikon). Immunohistochemistry of mouse liver was performed
as described previously78 using (a) anti-phospho-IRE1α (Abcam), (b) anti-
phospho-JNK (ThermoFisher Scientific), and (c) anti-cleaved lamin (small subunit,
Cell Signaling Technology) antibodies and 3,3′-diaminobenzidine (DAB) as the
chromogen. Phospho-IRE1α, phospho-JNK, and cleaved lamin A indices were
calculated by dividing the DAB-positive area by the region of interest (ROI), and
results are expressed as A.U. The cleavage of lamin is a well-characterized event in
apoptosis79. TUNEL staining was performed as previously described17, 22 using the
FragELTM DNA Fragmentation Detection Kit (EMD Millipore-Calbiochem) in
accordance with the manufacturer’s instructions. TUNEL-positive cells within
0.145 mm2 of the ROI were counted, and TUNEL indices were calculated as the
number of TUNEL-positive cells per unit area (in mm2); results are expressed
as A.U.
Ethics statement. This study was carried out in accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. All experiments involving animals were approved by
the Institutional Animal Care and Use Committees.
Statistical analysis. The degree of the spread of data was expressed by the
standard deviation (± s.d.). Two-tailed unpaired t-test was used to compare the
means of two groups. P< 0.05 was considered to be statistically significant. The
numbers of mice used in in vivo experiments were determined by (i) power ana-
lysis, assuming α error rate of 0.05, β error rate of 0.20, and expected difference of
25% and using Minitab 17 (State College, PA, USA) or (ii) our previous data set
and experience from the similar experiments performed in the past.
Data availability. The authors declare that the data supporting the findings of this
study are available within the paper and its Supplementary Information files. All
relevant data are available from the authors upon request.
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